A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma.
Chang Gon KimMin Hee HongDa Hee KimBrian Hyohyoung LeeHyunwook KimChan-Young OckGeoffrey KellyYoon Ji BangGamin KimJung Eun LeeChaeyeon KimSe-Heon KimHyun Jun HongYoung Min ParkNam Suk SimHeejung ParkJin Woo ParkChang Geol LeeKyung Hwan KimGoeun ParkInkyung JungDawoon HanJong Hoon KimJunha ChaHoyoung LeeMingu KangHeon SongChiyoon OumSeulki KimSukjun KimYoojoo LimSeunghee Kim-SchulzeMiriam MeradSun Och YoonHyun Je KimYoon Woo KohHye Ryun KimPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Preoperative D+/-T is feasible and may benefit patients with resectable HNSCC. Distinct changes in the tumor microenvironment and circulating immune cells were induced by each treatment regimen, warranting further investigation.